Literature DB >> 16485160

Hemithyroidectomy: the optimal initial surgical approach for individuals undergoing surgery for a cytological diagnosis of follicular neoplasm.

Sam M Wiseman1, Christopher Baliski, Robert Irvine, Donald Anderson, Graeme Wilkins, Douglas Filipenko, Hongbin Zhang, Sam Bugis.   

Abstract

BACKGROUND: The primary objective of this study was to determine the true proportion and optimal surgical approach for individuals undergoing thyroid operation for a suspicion of cancer based on a fine-needle aspiration biopsy diagnosis of a follicular neoplasm (FN). A secondary objective of this study was to determine whether patient characteristics could assist the clinician in predicting malignancy in this FN patient cohort.
METHODS: A retrospective chart, pathology, and cytology review of 370 consecutive primary thyroid operations was performed over a 4-year period at a tertiary care referral center. Clinical patient data were evaluated as an adjunct for predicting malignancy in the FN patient cohort. Univariate and multivariate analyses were used to investigate the association and the predictability.
RESULTS: A total of 80 (22%) of the 370 patients underwent hemithyroidectomy to rule out cancer based on clinical presentation with a fine-needle aspiration biopsy diagnosis of FN. Fifteen (19%) of the FN cases were diagnosed as cancer by histological analysis (4 follicular carcinomas and 11 papillary carcinomas). Hemithyroidectomy was considered adequate treatment for 77 patients (96%). No patient characteristic significantly predicted the presence of cancer by either univariate or multivariate analysis.
CONCLUSIONS: Overall, in the FN patient population, five hemithyroidectomies were performed to identify each cancer, and no further operation was required in 96% of patients. New diagnostic tools are needed to reduce the number of operations performed for benign pathology in patients with nodular thyroid disease and a needle biopsy diagnosis of FN.

Entities:  

Mesh:

Year:  2006        PMID: 16485160     DOI: 10.1245/ASO.2006.03.089

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

1.  Surgical treatment of thyroid follicular neoplasms: results of a retrospective analysis of a large clinical series.

Authors:  Giovanni Conzo; Nicola Avenia; Gian Luca Ansaldo; Piergiorgio Calò; Maurizio De Palma; Chiara Dobrinja; Giovanni Docimo; Claudio Gambardella; Marica Grasso; Celestino Pio Lombardi; Maria Rosa Pelizzo; Angela Pezzolla; Luciano Pezzullo; Micaela Piccoli; Lodovico Rosato; Giuseppe Siciliano; Stefano Spiezia; Ernesto Tartaglia; Francesco Tartaglia; Mario Testini; Giancarlo Troncone; Giuseppe Signoriello
Journal:  Endocrine       Date:  2016-04-13       Impact factor: 3.633

Review 2.  Diagnostic utility of galectin-3 in thyroid cancer.

Authors:  Connie G Chiu; Scott S Strugnell; Obi L Griffith; Steven J M Jones; Allen M Gown; Blair Walker; Ivan R Nabi; Sam M Wiseman
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

3.  Cyclin A and cyclin B1 overexpression in differentiated thyroid carcinoma.

Authors:  Asli Nar; Ozlem Ozen; Neslihan Bascil Tutuncu; Beyhan Demirhan
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

4.  Hemithyroidectomy is the preferred initial operative approach for an indeterminate fine needle aspiration biopsy diagnosis.

Authors:  Connie G Chiu; Reina Yao; Simon K Chan; Scott S Strugnell; Samuel Bugis; Robert Irvine; Donald Anderson; Blair Walker; Steven J Jones; Sam M Wiseman
Journal:  Can J Surg       Date:  2012-06       Impact factor: 2.089

5.  Atypia of undetermined significance on thyroid fine needle aspiration: surgical outcome and risk factors for malignancy.

Authors:  Young Jae Ryu; Youn Seung Jung; Hyun Chul Yoon; Min Jung Hwang; Sun Hyoung Shin; Jin Seong Cho; Ji Shin Lee; Hee Kyung Kim; Ho Cheol Kang; Hyo Soon Lim; Jung Han Yoon; Min Ho Park
Journal:  Ann Surg Treat Res       Date:  2014-02-24       Impact factor: 1.859

6.  The Diagnostic Usefulness of HMGA2, Survivin, CEACAM6, and SFN/14-3-3 δ in Follicular Thyroid Carcinoma.

Authors:  Min Hye Jang; Kyeong Cheon Jung; Hye Sook Min
Journal:  J Pathol Transl Med       Date:  2015-03-12

7.  WHICH FACTORS ARE ASSOCIATED WITH MALIGNANCY IN THYROID NODULES CLASSIFIED AS BETHESDA CATEGORY 3 (AUS/FLUS) AND HOW DO THEY INFLUENCE THE PATIENT'S MANAGEMENT?

Authors:  C Kaya; E Bozkurt; D Türkyılmaz Mut; M Mihmanli; M Uludağ
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Oct-Dec       Impact factor: 0.877

8.  Serum biomarkers of papillary thyroid cancer.

Authors:  Fawaz M Makki; S Mark Taylor; Ali Shahnavaz; Andrew Leslie; Jeffrey Gallant; Susan Douglas; Evelyn Teh; Jonathan Trites; Martin Bullock; Karen Inglis; Devanand M Pinto; Robert D Hart
Journal:  J Otolaryngol Head Neck Surg       Date:  2013-02-07

9.  Serum microRNA profiling to distinguish papillary thyroid cancer from benign thyroid masses.

Authors:  M Elise R Graham; Robert D Hart; Susan Douglas; Fawaz M Makki; Devanand Pinto; Angela L Butler; Martin Bullock; Matthew H Rigby; Jonathan R B Trites; S Mark Taylor; Rama Singh
Journal:  J Otolaryngol Head Neck Surg       Date:  2015-09-05

10.  Clinicopathological factors increased the risk of malignancy in thyroid nodules with atypical or follicular lesions of undetermined significance (AUS/FLUS) risk factor of malignancy in thyroid nodule with AUS/FLUS.

Authors:  In Ki Hong; Jun Ho Kim; Young Up Cho; Shin-Young Park; Sei Joong Kim
Journal:  Ann Surg Treat Res       Date:  2016-03-30       Impact factor: 1.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.